<DOC>
	<DOC>NCT02199288</DOC>
	<brief_summary>This prospective, open-label, multicenter, observational study will investigate the effectiveness and safety of MabThera SC (rituximab, subcutaneous) induction therapy in patients with non-Hodgkin's lymphoma, following a first initial treatment of MabThera IV (rituximab, intraveneous). Induction treatment period in the study is estimated to be 8 months.</brief_summary>
	<brief_title>Effectiveness, Safety &amp; Nurse Management Study of MabThera SC in Patients With Non-Hodgkin's Lymphoma: Real-Life Setting</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1. Indication according to the Summary of Product Characteristics (SPC) for MabThera SC formulation: As treatment of previously untreated patients with stage IIIIV follicular lymphoma in combination with chemotherapy As treatment of patients with CD20 positive diffuse large B cell nonHodgkin's lymphoma in combination with chemotherapy 2. At least 4 treatment cycles with MabThera is planned 3. Patients &gt;/= 18 years at inclusion 4. Patients written informed consent 5. Treatment decision to prescribe MabThera SC has been taken by the physician prior to recruitment into the study 1. Contraindications according to SPC for MabThera SC formulation: Hypersensitivity for the active substance or murine antibodies, hyaluronidase or any other excipients Active and severe infections Patients with severe immunsuppression 2. Patient included in clinical trials with experimental pharmaceuticals 3. Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>